UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 294

Sortiert nach

Impact of age at diagnosis of de novo metastatic prostate cancer on survival

Cancer, 2020-03, Vol.126 (5), p.986-993

2020

Link zum Volltext

Verfügbarkeit prüfen

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

The Prostate, 2018-09, Vol.78 (12), p.889-895

2018

Link zum Volltext

Verfügbarkeit prüfen

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

European urology, 2019-07, Vol.76 (1), p.89-97

2019

Link zum Volltext

Verfügbarkeit prüfen

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer

The Prostate, 2018-10, Vol.78 (14), p.1053-1062

2018

Link zum Volltext

Verfügbarkeit prüfen

Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors

American journal of clinical oncology, 2018-10, Vol.41 (10), p.949-952

2018

Link zum Volltext

Verfügbarkeit prüfen

Renal cell carcinoma: a review of biology and pathophysiology [version 1; peer review: 2 approved]

F1000 research, 2018, Vol.7, p.307-307

2018

Link zum Volltext

Verfügbarkeit prüfen

Complications of Androgen Deprivation Therapy in Men With Prostate Cancer

Oncology (Williston Park, N.Y.), 2018-09, Vol.32 (9), p.470-474

2018

Link zum Volltext

Verfügbarkeit prüfen

A comparison of survival by site of metastatic resection (MR) in metastatic colorectal cancer (mCRC)

Clinical colorectal cancer, 2017-06, Vol.16 (2), p.e23-e28

2017

Link zum Volltext

Verfügbarkeit prüfen

Hypoglycaemia following upper gastrointestinal surgery: case report and review of the literature

BMC gastroenterology, 2010-07, Vol.10 (1), p.77-77, Article 77

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

The Journal of urology, 2020-04, Vol.203 (4), p.690

2020

Link zum Volltext

Verfügbarkeit prüfen

Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

Cancer, 2016-10, Vol.122 (20), p.3127-3135

2016

Link zum Volltext

Verfügbarkeit prüfen

Genomic evolution and chemoresistance in germ-cell tumours

Nature (London), 2016-12, Vol.540 (7631), p.114-118

2016

Link zum Volltext

Verfügbarkeit prüfen

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry

Journal of clinical oncology, 2018-12, Vol.36 (34), p.JCO1800210-3387

2018

Link zum Volltext

Verfügbarkeit prüfen

Point-Prostate Cancer Genomic Analysis: Routine or Research Only?

Oncology (Williston Park, N.Y.), 2018-12, Vol.32 (12), p.607-609

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer

Cancer, 2017-05, Vol.123 (9), p.1536-1544

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations

Proteins, structure, function, and bioinformatics, 2006-11, Vol.65 (2), p.331-346

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT207: A phase II trial using grape seed extract for prostate cancer patients with non-metastatic PSA progression after local therapy

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT207-CT207

2020

Link zum Volltext

Verfügbarkeit prüfen

DNA damage and repair (DDR) gene variants and outcomes in localized and metastatic prostate cancer (mPC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.304-304

2018

Link zum Volltext

Verfügbarkeit prüfen

Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.331-331

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.184-184

2018

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.600-600

2019

Link zum Volltext

Verfügbarkeit prüfen

Age, race, and survival of men with de novo distant metastatic prostate cancer (M1PC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.5031-5031

2016

Link zum Volltext

Verfügbarkeit prüfen

(S031) Racial Disparities in Proton Beam Therapy Utilization in the United States

International journal of radiation oncology, biology, physics, 2017-06, Vol.98 (2), p.E10-E10

2017

Link zum Volltext

Verfügbarkeit prüfen

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy

Journal of clinical oncology, 2016-03, Vol.34 (7), p.714-720

2016

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer

Prostate cancer and prostatic diseases, 2022-02, Vol.25 (2), p.199-207

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(273)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Impact of age at diagnosis of de novo metastatic prostate cancer on survival

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer

Quantifying Decreased Radiation Exposure From Modern CT Scan Technology and Surveillance Programs of Germ Cell Tumors

Renal cell carcinoma: a review of biology and pathophysiology [version 1; peer review: 2 approved]

Complications of Androgen Deprivation Therapy in Men With Prostate Cancer

A comparison of survival by site of metastatic resection (MR) in metastatic colorectal cancer (mCRC)

Hypoglycaemia following upper gastrointestinal surgery: case report and review of the literature

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

Genomic evolution and chemoresistance in germ-cell tumours

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry

Point-Prostate Cancer Genomic Analysis: Routine or Research Only?

Impact of ethnicity on the outcome of men with metastatic, hormone‐sensitive prostate cancer

Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations

Abstract CT207: A phase II trial using grape seed extract for prostate cancer patients with non-metastatic PSA progression after local therapy

DNA damage and repair (DDR) gene variants and outcomes in localized and metastatic prostate cancer (mPC)

Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC)

Tumor suppressor aberrations and outcomes in localized and metastatic hormone sensitive prostate cancer (PrCa)

Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results

Age, race, and survival of men with de novo distant metastatic prostate cancer (M1PC)

(S031) Racial Disparities in Proton Beam Therapy Utilization in the United States

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer

Suchergebnisse filtern